

Lieuwe de Haan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4225253/publications.pdf>

Version: 2024-02-01

180
papers

8,219
citations

76326

40
h-index

60623

81
g-index

187
all docs

187
docs citations

187
times ranked

10428
citing authors

#	ARTICLE	IF	CITATIONS
1	Longitudinal clinical and functional outcome in distinct cognitive subgroups of first-episode psychosis: a cluster analysis. <i>Psychological Medicine</i> , 2023, 53, 2317-2327.	4.5	13
2	Use of multiple polygenic risk scores for distinguishing schizophrenia-spectrum disorder and affective psychosis categories in a first-episode sample; the EU-GEI study. <i>Psychological Medicine</i> , 2023, 53, 3396-3405.	4.5	9
3	Sustained specialized and family treatment in first-episode schizophrenia or related disorders: a 5-year randomized controlled trial. <i>Psychological Medicine</i> , 2023, 53, 4316-4323.	4.5	1
4	The incidence of psychotic disorders among migrants and minority ethnic groups in Europe: findings from the multinational EU-GEI study. <i>Psychological Medicine</i> , 2022, 52, 1376-1385.	4.5	17
5	Migration history and risk of psychosis: results from the multinational EU-GEI study. <i>Psychological Medicine</i> , 2022, 52, 2972-2984.	4.5	22
6	Medication strategies in first episode psychosis patients: A survey among psychiatrists. <i>Microbial Biotechnology</i> , 2022, 16, 139-146.	1.7	6
7	Perceived major experiences of discrimination, ethnic group, and risk of psychosis in a six-country case-control study. <i>Psychological Medicine</i> , 2022, 52, 3668-3676.	4.5	7
8	Impact of Comorbid Affective Disorders on Longitudinal Clinical Outcomes in Individuals at Ultra-high Risk for Psychosis. <i>Schizophrenia Bulletin</i> , 2022, 48, 100-110.	4.3	9
9	Tapering antipsychotic medication: practical considerations. <i>Psychological Medicine</i> , 2022, 52, 32-35.	4.5	9
10	The association of plasma inflammatory markers with omega-3 fatty acids and their mediating role in psychotic symptoms and functioning: An analysis of the NEURAPRO clinical trial. <i>Brain, Behavior, and Immunity</i> , 2022, 99, 147-156.	4.1	2
11	Cross-classified multilevel models improved standard error estimates of covariates in clinical outcomes – a simulation study. <i>Journal of Clinical Epidemiology</i> , 2022, 145, 39-46.	5.0	2
12	It might be a wonderful opportunity when patients with a psychotic disorder use cannabis. <i>Psychological Medicine</i> , 2022, 52, 601-602.	4.5	1
13	Facial Emotion Recognition in Psychosis and Associations With Polygenic Risk for Schizophrenia: Findings From the Multi-Center EU-GEI Case-Control Study. <i>Schizophrenia Bulletin</i> , 2022, 48, 1104-1114.	4.3	9
14	The Puzzle of Functional Recovery in Schizophrenia-Spectrum Disorders – Replicating a Network Analysis Study. <i>Schizophrenia Bulletin</i> , 2022, 48, 871-880.	4.3	9
15	Efficacy of Acceptance and Commitment Therapy in Daily Life in Early Psychosis: Results from the Multi-Center INTERACT Randomized Controlled Trial. <i>Psychotherapy and Psychosomatics</i> , 2022, 91, 411-423.	8.8	12
16	Machine learning based prediction and the influence of complement Coagulation pathway proteins on clinical outcome: Results from the NEURAPRO trial. <i>Brain, Behavior, and Immunity</i> , 2022, 103, 50-60.	4.1	4
17	Mapping genomic loci implicates genes and synaptic biology in schizophrenia. <i>Nature</i> , 2022, 604, 502-508.	27.8	929
18	Identifying Electroencephalography Biomarkers in Individuals at Clinical High Risk for Psychosis in an International Multi-Site Study. <i>Frontiers in Psychiatry</i> , 2022, 13, 828376.	2.6	1

#	ARTICLE	IF	CITATIONS
19	Autistic traits and alcohol use in adolescents within the general population. <i>European Child and Adolescent Psychiatry</i> , 2022, , 1.	4.7	0
20	Measuring process indicators and adverse events to assess the quality of care for inpatients with psychosis. <i>Journal of Mental Health</i> , 2021, 30, 564-570.	1.9	0
21	Association of extent of cannabis use and psychotic like intoxication experiences in a multi-national sample of first episode psychosis patients and controls. <i>Psychological Medicine</i> , 2021, 51, 2074-2082.	4.5	7
22	Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case-control study. <i>Psychological Medicine</i> , 2021, 51, 1329-1337.	4.5	38
23	Jumping to conclusions, general intelligence, and psychosis liability: findings from the multi-centre EU-GEI case-control study. <i>Psychological Medicine</i> , 2021, 51, 623-633.	4.5	34
24	Early predictors of mental health in mid-adulthood. <i>Microbial Biotechnology</i> , 2021, 15, 158-166.	1.7	4
25	Autistic traits in psychotic disorders: prevalence, familial risk, and impact on social functioning. <i>Psychological Medicine</i> , 2021, 51, 1704-1713.	4.5	24
26	Meta-analysis of cognitive functioning in patients with psychotic disorders and obsessive-compulsive symptoms. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2021, 271, 689-706.	3.2	6
27	Dysregulated Lipid Metabolism Precedes Onset of Psychosis. <i>Biological Psychiatry</i> , 2021, 89, 288-297.	1.3	42
28	Reliability and Reproducibility of Neuromelanin-Sensitive Imaging of the Substantia Nigra: A Comparison of Three Different Sequences. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 53, 712-721.	3.4	29
29	A comparison of depressive symptom profiles between current major depressive disorder and schizophrenia spectrum disorder. <i>Journal of Psychiatric Research</i> , 2021, 135, 143-151.	3.1	9
30	Smoking and the risk for bipolar disorder: evidence from a bidirectional Mendelian randomisation study. <i>British Journal of Psychiatry</i> , 2021, 218, 88-94.	2.8	54
31	Study protocol of a randomized, double-blind, placebo-controlled, multi-center trial to treat antipsychotic-induced weight gain: the Metformin-Lifestyle in antipsychotic users (MELIA) trial. <i>BMC Psychiatry</i> , 2021, 21, 4.	2.6	3
32	Greater preference for eveningness is associated with negative symptoms in an ultra-high risk for psychosis sample. <i>Microbial Biotechnology</i> , 2021, 15, 1793-1798.	1.7	4
33	Obsessive-Compulsive Symptoms and Other Symptoms of the At-risk Mental State for Psychosis: A Network Perspective. <i>Schizophrenia Bulletin</i> , 2021, 47, 1018-1028.	4.3	10
34	Changes in peripheral blood compounds following psychopharmacological treatment in drug-naïve first-episode patients with either schizophrenia or major depressive disorder: a meta-analysis. <i>Psychological Medicine</i> , 2021, 51, 538-549.	4.5	17
35	The association between sleep disturbances and negative symptom severity in patients with non-affective psychotic disorders, unaffected siblings and healthy controls. <i>Psychiatry Research</i> , 2021, 297, 113728.	3.3	0
36	Skin autofluorescence of advanced glycation end products and mortality in affective disorders in the lifelines cohort study: A mediation analysis. <i>Journal of Affective Disorders</i> , 2021, 282, 1082-1089.	4.1	2

#	ARTICLE	IF	CITATIONS
37	Relationship between social cognition, general cognition, and risk for suicide in individuals with a psychotic disorder. <i>Schizophrenia Research</i> , 2021, 231, 227-236.	2.0	8
38	Duration of Untreated Psychosis in First-Episode Psychosis is not Associated With Common Genetic Variants for Major Psychiatric Conditions: Results From the Multi-Center EU-GEI Study. <i>Schizophrenia Bulletin</i> , 2021, 47, 1653-1662.	4.3	4
39	Active Ingredients and Mechanisms of Change in Motivational Interviewing for Smoking Cessation in Patients With Coronary Artery Disease: A Mixed Methods Study. <i>Frontiers in Psychology</i> , 2021, 12, 599203.	2.1	4
40	Autistic Symptoms and Social Functioning in Psychosis: A Network Approach. <i>Schizophrenia Bulletin</i> , 2021, , .	4.3	16
41	Association of <i>Toxoplasma gondii</i> Seropositivity With Cognitive Function in Healthy People. <i>JAMA Psychiatry</i> , 2021, 78, 1103.	11.0	20
42	The Community Assessment of Psychic Experiences: Optimal cutoff scores for detecting individuals with a psychotic disorder. <i>International Journal of Methods in Psychiatric Research</i> , 2021, 30, e1893.	2.1	9
43	The continuity of effect of schizophrenia polygenic risk score and patterns of cannabis use on transdiagnostic symptom dimensions at first-episode psychosis: findings from the EU-GEI study. <i>Translational Psychiatry</i> , 2021, 11, 423.	4.8	12
44	Rising co-payments and continuity of healthcare for Dutch patients with bipolar disorder: retrospective longitudinal cohort study. <i>BJPsych Open</i> , 2021, 7, .	0.7	3
45	Ethnic discrimination and depressed mood: The role of autonomic regulation. <i>Journal of Psychiatric Research</i> , 2021, 144, 110-117.	3.1	0
46	The relationship of symptom dimensions with premorbid adjustment and cognitive characteristics at first episode psychosis: Findings from the EU-GEI study. <i>Schizophrenia Research</i> , 2021, 236, 69-79.	2.0	4
47	The association between migrant status and transition in an ultra-high risk for psychosis population. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2021, 56, 943-952.	3.1	5
48	Momentary Manifestations of Negative Symptoms as Predictors of Clinical Outcomes in People at High Risk for Psychosis: Experience Sampling Study. <i>JMIR Mental Health</i> , 2021, 8, e30309.	3.3	4
49	Designing and Testing of a Health-Economic Markov Model for Prevention and Treatment of Early Psychosis. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2020, 20, 269-279.	1.4	11
50	The NEURAPRO Biomarker Analysis: Long-Chain Omega-3 Fatty Acids Improve 6-Month and 12-Month Outcomes in Youths at Ultra-High Risk for Psychosis. <i>Biological Psychiatry</i> , 2020, 87, 243-252.	1.3	48
51	Supplementation with the omega-3 long chain polyunsaturated fatty acids: Changes in the concentrations of omega-3 index, fatty acids and molecular phospholipids of people at ultra high risk of developing psychosis. <i>Schizophrenia Research</i> , 2020, 226, 52-60.	2.0	8
52	Premorbid Adjustment and IQ in Patients With First-Episode Psychosis: A Multisite Case-Control Study of Their Relationship With Cannabis Use. <i>Schizophrenia Bulletin</i> , 2020, 46, 517-529.	4.3	14
53	Stressful experiences affect the course of co-occurring obsessive-compulsive and psychotic symptoms: A focus on within-subject processes. <i>Schizophrenia Research</i> , 2020, 216, 69-76.	2.0	2
54	Childhood trauma and coping in patients with psychotic disorders and obsessive-compulsive symptoms and in un-affected siblings. <i>Child Abuse and Neglect</i> , 2020, 99, 104243.	2.6	12

#	ARTICLE	IF	CITATIONS
55	Trajectories of symptom severity and functioning over a three-year period in a psychosis high-risk sample: A secondary analysis of the Neurapro trial. <i>Behaviour Research and Therapy</i> , 2020, 124, 103527.	3.1	16
56	Influence of nursing staff attitudes and characteristics on the use of coercive measures in acute mental health services – A systematic review. <i>Journal of Psychiatric and Mental Health Nursing</i> , 2020, 27, 446-459.	2.1	55
57	T34. THE IMPACT OF ANTIDEPRESSANT USE ON THE TRANSITION TO PSYCHOSIS RATE IN THE NEURAPRO TRIAL. <i>Schizophrenia Bulletin</i> , 2020, 46, S244-S245.	4.3	0
58	T246. RISK FACTORS FOR PSYCHOTIC RELAPSE IN CHRONIC SCHIZOPHRENIA AFTER DOSE-REDUCTION OR DISCONTINUATION OF ANTIPSYCHOTICS: A SYSTEMATIC REVIEW AND META-ANALYSIS. <i>Schizophrenia Bulletin</i> , 2020, 46, S326-S326.	4.3	2
59	Shortening Duration of Treatment Resistance: The Next Step in the Treatment of Schizophrenia. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	1.7	3
60	Skin autofluorescence of advanced glycation end products and course of affective disorders in the lifelines cohort study, a prospective investigation. <i>Journal of Affective Disorders</i> , 2020, 276, 424-432.	4.1	1
61	Association between skin autofluorescence of advanced glycation end products and affective disorders in the lifelines cohort study. <i>Journal of Affective Disorders</i> , 2020, 275, 230-237.	4.1	8
62	Reply to interleukin-6 in schizophrenia: Cause of death matters. <i>Brain, Behavior, and Immunity</i> , 2020, 90, 383-384.	4.1	1
63	S175. CLINICAL OUTCOMES IN PEOPLE AT HIGH RISK FOR PSYCHOSIS RELATED TO INTERACTIONS BETWEEN POLYGENIC RISK SCORES AND CHILDHOOD ADVERSITY. <i>Schizophrenia Bulletin</i> , 2020, 46, S104-S104.	4.3	0
64	S53. DELINEATING SOCIAL COGNITION IN AUTISM AND PSYCHOSIS. <i>Schizophrenia Bulletin</i> , 2020, 46, S53-S53.	4.3	0
65	Insight, personality, and symptoms among individuals with psychosis: Cross-sectional and longitudinal relationships. <i>Schizophrenia Research</i> , 2020, 222, 243-250.	2.0	4
66	Accumulation rate of advanced glycation end products in recent onset psychosis: A longitudinal study. <i>Psychiatry Research</i> , 2020, 291, 113192.	3.3	9
67	To continue or not to continue? Antipsychotic medication maintenance versus dose-reduction/discontinuation in first episode psychosis: HAMLETT, a pragmatic multicenter single-blind randomized controlled trial. <i>Trials</i> , 2020, 21, 147.	1.6	41
68	Risk Factors for Psychotic Relapse After Dose Reduction or Discontinuation of Antipsychotics in Patients With Chronic Schizophrenia: A Systematic Review and Meta-analysis. <i>Schizophrenia Bulletin Open</i> , 2020, 1, .	1.7	19
69	The European Network of National Schizophrenia Networks Studying Gene-Environment Interactions (EU-GEI): Incidence and First-Episode Case-Control Programme. <i>Social Psychiatry and Psychiatric Epidemiology</i> , 2020, 55, 645-657.	3.1	41
70	Staging and profiling for schizophrenia spectrum disorders: Inter-rater reliability after a short training course. <i>Progress in Neuro-Psychopharmacology and Biological Psychiatry</i> , 2020, 99, 109856.	4.8	3
71	Altered peripheral blood compounds in drug-naïve first-episode patients with either schizophrenia or major depressive disorder: a meta-analysis. <i>Brain, Behavior, and Immunity</i> , 2020, 88, 547-558.	4.1	96
72	Active Ingredients and Mechanisms of Change in Motivational Interviewing for Medication Adherence. A Mixed Methods Study of Patient-Therapist Interaction in Patients With Schizophrenia. <i>Frontiers in Psychiatry</i> , 2020, 11, 78.	2.6	14

#	ARTICLE	IF	CITATIONS
73	M83. AUTISTIC TRAITS AS LINKING PIN TO SOCIAL FUNCTIONING IN PSYCHOSIS: A NETWORK APPROACH. <i>Schizophrenia Bulletin</i> , 2020, 46, S166-S166.	4.3	0
74	Early Parental Death and Risk of Psychosis in Offspring: A Six-Country Case-Control Study. <i>Journal of Clinical Medicine</i> , 2019, 8, 1081.	2.4	10
75	Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial. <i>Frontiers in Psychiatry</i> , 2019, 10, 393.	2.6	22
76	Increased prevalence of ECG suspicious for Brugada Syndrome in recent onset schizophrenia spectrum disorders. <i>Schizophrenia Research</i> , 2019, 210, 59-65.	2.0	12
77	The Unhealthy Chicken or the Unhealthy Egg: Quitting Smoking Matters: Response to Hajek et al.. <i>American Journal of Psychiatry</i> , 2019, 176, 575-576.	7.2	0
78	Plasma dopa decarboxylase activity in treatment-resistant recent-onset psychosis patients. <i>Therapeutic Advances in Psychopharmacology</i> , 2019, 9, 204512531987234.	2.7	0
79	Use of Natural Language Processing to identify Obsessive Compulsive Symptoms in patients with schizophrenia, schizoaffective disorder or bipolar disorder. <i>Scientific Reports</i> , 2019, 9, 14146.	3.3	27
80	Individualized Prediction of Transition to Psychosis in 1,676 Individuals at Clinical High Risk: Development and Validation of a Multivariable Prediction Model Based on Individual Patient Data Meta-Analysis. <i>Frontiers in Psychiatry</i> , 2019, 10, 345.	2.6	29
81	“But I did not touch nobody!” Patients' and nurses' perspectives and recommendations after aggression on psychiatric wards: A qualitative study. <i>Journal of Advanced Nursing</i> , 2019, 75, 2845-2854.	3.3	11
82	Increased serum levels of leptin and insulin in both schizophrenia and major depressive disorder: A cross-disorder proteomics analysis. <i>European Neuropsychopharmacology</i> , 2019, 29, 835-846.	0.7	26
83	The Association Between Familial Risk and Brain Abnormalities Is Disease Specific: An ENIGMA-Relatives Study of Schizophrenia and Bipolar Disorder. <i>Biological Psychiatry</i> , 2019, 86, 545-556.	1.3	67
84	O10.7. SIMILARLY ALTERED PROTEIN MARKERS IN DRUG-NAÏVE FIRST-EPISEODE PATIENTS WITH SCHIZOPHRENIA OR MAJOR DEPRESSIVE DISORDER. A META-ANALYSIS. <i>Schizophrenia Bulletin</i> , 2019, 45, S192-S193.	4.3	0
85	Longitudinal evidence for a relation between depressive symptoms and quality of life in schizophrenia using structural equation modeling. <i>Schizophrenia Research</i> , 2019, 208, 82-89.	2.0	16
86	Driving us mad: the association of <i>Toxoplasma gondii</i> with suicide attempts and traffic accidents – a systematic review and meta-analysis. <i>Psychological Medicine</i> , 2019, 49, 1608-1623.	4.5	47
87	T68. SUBCLINICAL PSYCHOTIC PHENOMENA ARE ASSOCIATED WITH MARKERS OF AN ALTERED METABOLISM IN A LARGE COMMUNITY SAMPLE. <i>Schizophrenia Bulletin</i> , 2019, 45, S230-S231.	4.3	0
88	The contribution of cannabis use to variation in the incidence of psychotic disorder across Europe (EU-GEI): a multicentre case-control study. <i>Lancet Psychiatry</i> , 2019, 6, 427-436.	7.4	528
89	The relationship between childhood trauma and clinical characteristics in ultra-high risk for psychosis youth. <i>Psychosis</i> , 2019, 11, 28-41.	0.8	6
90	Reply to: New Meta- and Mega-analyses of Magnetic Resonance Imaging Findings in Schizophrenia: Do They Really Increase Our Knowledge About the Nature of the Disease Process?. <i>Biological Psychiatry</i> , 2019, 85, e35-e39.	1.3	5

#	ARTICLE	IF	CITATIONS
91	Reduced activity and connectivity of left amygdala in patients with schizophrenia treated with clozapine or olanzapine. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2019, 269, 931-940.	3.2	8
92	Smoking, symptoms, and quality of life in patients with psychosis, siblings, and healthy controls: a prospective, longitudinal cohort study. <i>Lancet Psychiatry</i> , 2019, 6, 25-34.	7.4	30
93	Patterns of obsessive-compulsive symptoms and social functioning in schizophrenia; a replication study. <i>Psychiatry Research</i> , 2019, 271, 421-427.	3.3	1
94	Transdiagnostic dimensions of psychopathology at first episode psychosis: findings from the multinational EU-GEI study. <i>Psychological Medicine</i> , 2019, 49, 1378-1391.	4.5	69
95	Treating depressive episodes or symptoms in patients with schizophrenia. <i>CNS Spectrums</i> , 2019, 24, 239-248.	1.2	19
96	Clozapine and Long-Term Mortality Risk in Patients With Schizophrenia: A Systematic Review and Meta-analysis of Studies Lasting 1.1â€“12.5 Years. <i>Schizophrenia Bulletin</i> , 2019, 45, 315-329.	4.3	141
97	O11.3. A LONGITUDINAL ANALYSIS OF THE EFFECTS OF NEUROTICISM AND EXTRAVERSION ON SUBJECTIVE WELL-BEING IN PATIENTS WITH SCHIZOPHRENIA. <i>Schizophrenia Bulletin</i> , 2018, 44, S107-S107.	4.3	0
98	The role of cognitive functioning in the relationship between childhood trauma and a mixed phenotype of affective-anxious-psychotic symptoms in psychotic disorders. <i>Schizophrenia Research</i> , 2018, 192, 262-268.	2.0	10
99	Comparing the effect of clozapine and risperidone on cue reactivity in male patients with schizophrenia and a cannabis use disorder: A randomized fMRI study. <i>Schizophrenia Research</i> , 2018, 194, 32-38.	2.0	20
100	Obsessiveâ€“compulsive symptoms and overall psychopathology in psychotic disorders: longitudinal assessment of patients and siblings. <i>European Archives of Psychiatry and Clinical Neuroscience</i> , 2018, 268, 279-289.	3.2	18
101	Child Maltreatment and Clinical Outcome in Individuals at Ultra-High Risk for Psychosis in the EU-GEI High Risk Study. <i>Schizophrenia Bulletin</i> , 2018, 44, 584-592.	4.3	38
102	Medicinal cannabis (Bedrolite) substitution therapy in inpatients with a psychotic disorder and a comorbid cannabis use disorder: A case series. <i>Journal of Psychopharmacology</i> , 2018, 32, 353-356.	4.0	13
103	A state-independent network of depressive, negative and positive symptoms in male patients with schizophrenia spectrum disorders. <i>Schizophrenia Research</i> , 2018, 193, 232-239.	2.0	58
104	Treated Incidence of Psychotic Disorders in the Multinational EU-GEI Study. <i>JAMA Psychiatry</i> , 2018, 75, 36.	11.0	235
105	T49. THE NEURAPRO STUDY: ADHERENCE TO STUDY MEDICATION. <i>Schizophrenia Bulletin</i> , 2018, 44, S132-S133.	4.3	5
106	F25. NEURAPRO REVISITED: INCREASES IN LONG-CHAIN OMEGA-3 FATTY ACIDS IMPROVE FUNCTIONAL AND SYMPTOMATIC OUTCOMES IN ULTRAHIGH RISK PATIENTS. <i>Schizophrenia Bulletin</i> , 2018, 44, S228-S228.	4.3	1
107	Economic evaluation of brief cognitive behavioural therapy for social activation in recent-onset psychosis. <i>PLoS ONE</i> , 2018, 13, e0206236.	2.5	8
108	O5.1. CLOZAPINE AND LONG-TERM MORTALITY RISK IN PATIENTS WITH SCHIZOPHRENIA: PRELIMINARY RESULTS FROM A META-ANALYSIS. <i>Schizophrenia Bulletin</i> , 2018, 44, S86-S86.	4.3	5

#	ARTICLE	IF	CITATIONS
109	O8.8. NEUROCOGNITION IN ULTRA-HIGHRISK INDIVIDUALS AND RELATIONSHIP TO TRANSITION TO PSYCHOSIS, DEPRESSIVE DISORDER, AND FUNCTIONING: FINDINGS FROM THE NEURAPRO TRIAL. Schizophrenia Bulletin, 2018, 44, S99-S99.	4.3	1
110	Cortical Brain Abnormalities in 4474 Individuals With Schizophrenia and 5098 Control Subjects via the Enhancing Neuro Imaging Genetics Through Meta Analysis (ENIGMA) Consortium. Biological Psychiatry, 2018, 84, 644-654.	1.3	627
111	Association Between Smoking Behavior and Cognitive Functioning in Patients With Psychosis, Siblings, and Healthy Control Subjects: Results From a Prospective 6-Year Follow-Up Study. American Journal of Psychiatry, 2018, 175, 1121-1128.	7.2	49
112	The impact of affective symptoms on personal recovery of patients with severe mental illness. International Journal of Social Psychiatry, 2018, 64, 521-527.	3.1	14
113	Dose reduction of high-dose first-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: A 1-year double-blind randomized clinical trial. European Neuropsychopharmacology, 2018, 28, 1024-1034.	0.7	6
114	Predictors of Adverse Events and Medical Errors Among Adult Inpatients of Psychiatric Units of Acute Care General Hospitals. Psychiatric Services, 2018, 69, 1087-1094.	2.0	14
115	F53. DOSE REDUCTION OF HIGH-DOSE FIRST-GENERATION ANTIPSYCHOTICS OR SWITCH TO ZIPRASIDONE IN LONG-STAY PATIENTS WITH SCHIZOPHRENIA: A 1-YEAR DOUBLE-BLIND RANDOMIZED CLINICAL TRIAL. Schizophrenia Bulletin, 2018, 44, S239-S240.	4.3	1
116	Medication adherence in patients with schizophrenia: a qualitative study of the patient process in motivational interviewing. BMC Psychiatry, 2018, 18, 135.	2.6	31
117	A symptom network structure of the psychosis spectrum. Schizophrenia Research, 2017, 189, 75-83.	2.0	56
118	The associations between childhood trauma, neuroticism and comorbid obsessive-compulsive symptoms in patients with psychotic disorders. Psychiatry Research, 2017, 254, 48-53.	3.3	9
119	Effect of ω -3 Polyunsaturated Fatty Acids in Young People at Ultrahigh Risk for Psychotic Disorders. JAMA Psychiatry, 2017, 74, 19.	11.0	216
120	Nursing Staff Factors Contributing to Seclusion in Acute Mental Health Care – An Explorative Cohort Study. Issues in Mental Health Nursing, 2017, 38, 584-589.	1.2	20
121	Memantine add-on to clozapine treatment for residual negative symptoms of schizophrenia. Psychopharmacology, 2017, 234, 3535-3536.	3.1	1
122	New Research Strategy for Measuring Pre- and Postnatal Metal Dysregulation in Psychotic Disorders. Schizophrenia Bulletin, 2017, 43, 1153-1157.	4.3	11
123	Treatment for Negative Symptoms in Schizophrenia: A Comprehensive Review. Drugs, 2017, 77, 1423-1459.	10.9	63
124	The effect of childhood adversity on 4-year outcome in individuals at ultra high risk for psychosis in the Dutch Early Detection Intervention Evaluation (EDIE-NL) Trial. Psychiatry Research, 2017, 247, 55-62.	3.3	23
125	Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. Nature Genetics, 2017, 49, 27-35.	21.4	838
126	174.2 Psychosis Prediction: Stratification of Risk Estimation With Information-Processing and Premorbid Functioning Variables. Schizophrenia Bulletin, 2017, 43, S87-S88.	4.3	0

#	ARTICLE	IF	CITATIONS
127	Preliminary validation of a clinical staging model in schizophrenia and related disorders. <i>Clinical Schizophrenia and Related Psychoses</i> , 2017, , .	1.4	9
128	Advanced Glycation End Products in Recent-Onset Psychosis Indicate Early Onset of Cardiovascular Risk. <i>Journal of Clinical Psychiatry</i> , 2017, 78, 1395-1401.	2.2	16
129	Schizophrenia in the Netherlands: Continuity of Care with Better Quality of Care for Less Medical Costs. <i>PLoS ONE</i> , 2016, 11, e0157150.	2.5	15
130	Cortical Morphology Differences in Subjects at Increased Vulnerability for Developing a Psychotic Disorder: A Comparison between Subjects with Ultra-High Risk and 22q11.2 Deletion Syndrome. <i>PLoS ONE</i> , 2016, 11, e0159928.	2.5	23
131	In vivo (R)-[11C]PK11195 PET imaging of 18kDa translocator protein in recent onset psychosis. <i>NPJ Schizophrenia</i> , 2016, 2, 16031.	3.6	63
132	COMT Val 158 Met genotype and cannabis use in people with an At Risk Mental State for psychosis: Exploring Gene x Environment interactions. <i>Schizophrenia Research</i> , 2016, 174, 24-28.	2.0	22
133	Evidence for Genetic Overlap Between Schizophrenia and Age at First Birth in Women. <i>JAMA Psychiatry</i> , 2016, 73, 497.	11.0	51
134	Developmental Trajectories of Impaired Community Functioning in Schizophrenia. <i>JAMA Psychiatry</i> , 2016, 73, 48.	11.0	26
135	Mortality and Its Determinants in Late-Life Schizophrenia: A 5-Year Prospective Study in a Dutch Catchment Area. <i>American Journal of Geriatric Psychiatry</i> , 2016, 24, 272-277.	1.2	17
136	Grey Matter Changes Associated with Heavy Cannabis Use: A Longitudinal sMRI Study. <i>PLoS ONE</i> , 2016, 11, e0152482.	2.5	62
137	A comparison of indices for identifying the number of clusters in hierarchical clustering: A study on cognition in schizophrenia patients. <i>Communications in Statistics Case Studies Data Analysis and Applications</i> , 2015, 1, 98-113.	0.3	7
138	Structural MRI Differences between Patients with and without First Rank Symptoms: A Delusion?. <i>Frontiers in Psychiatry</i> , 2015, 6, 107.	2.6	0
139	Reduced maternal levels of common viruses during pregnancy predict offspring psychosis: Potential role of enhanced maternal immune activity?. <i>Schizophrenia Research</i> , 2015, 166, 248-254.	2.0	13
140	Emotion processing in schizophrenia is state and trait dependent. <i>Schizophrenia Research</i> , 2015, 161, 392-398.	2.0	26
141	Trauma and recent life events in individuals at ultra high risk for psychosis: Review and meta-analysis. <i>Schizophrenia Research</i> , 2015, 161, 143-149.	2.0	147
142	Grey matter, an endophenotype for schizophrenia? A voxel-based morphometry study in siblings of patients with schizophrenia. <i>Journal of Psychiatry and Neuroscience</i> , 2015, 40, 207-213.	2.4	9
143	Brain volume in male patients with recent onset schizophrenia with and without cannabis use disorders. <i>Journal of Psychiatry and Neuroscience</i> , 2015, 40, 197-206.	2.4	21
144	Specificity of facial emotion recognition impairments in patients with multi-episode schizophrenia. <i>Schizophrenia Research: Cognition</i> , 2015, 2, 12-19.	1.3	25

#	ARTICLE	IF	CITATIONS
145	Viral metagenomics in drug-naïve, first-onset schizophrenia patients with prominent negative symptoms. <i>Psychiatry Research</i> , 2015, 229, 678-684.	3.3	2
146	Childhood trauma and clinical outcome in patients at ultra-high risk of transition to psychosis. <i>Schizophrenia Research</i> , 2015, 169, 193-198.	2.0	40
147	Impact of DSM-5 Changes on the Diagnosis and Acute Treatment of Schizophrenia. <i>Schizophrenia Bulletin</i> , 2015, 41, 637-643.	4.3	24
148	Identifying Gene-Environment Interactions in Schizophrenia: Contemporary Challenges for Integrated, Large-scale Investigations. <i>Schizophrenia Bulletin</i> , 2014, 40, 729-736.	4.3	229
149	Systematic review of ERP and fMRI studies investigating inhibitory control and error processing in people. <i>Journal of Psychiatry and Neuroscience</i> , 2014, 39, 149-169.	2.4	294
150	Pre-pulse inhibition and striatal dopamine in subjects at an ultra-high risk for psychosis. <i>Journal of Psychopharmacology</i> , 2014, 28, 553-560.	4.0	27
151	Can quantitative EEG measures predict clinical outcome in subjects at Clinical High Risk for psychosis? A prospective multicenter study. <i>Schizophrenia Research</i> , 2014, 153, 42-47.	2.0	48
152	The obsessive compulsive spectrum in schizophrenia, a meta-analysis and meta-regression exploring prevalence rates. <i>Schizophrenia Research</i> , 2014, 152, 458-468.	2.0	153
153	Psychosis Prediction: Stratification of Risk Estimation With Information-Processing and Premorbid Functioning Variables. <i>Schizophrenia Bulletin</i> , 2014, 40, 1482-1490.	4.3	91
154	Geographic variation in efficacy of atypical antipsychotics for the acute treatment of schizophrenia – An individual patient data meta-analysis. <i>European Neuropsychopharmacology</i> , 2014, 24, 1067-1077.	0.7	10
155	Dissociable morphometric profiles of the affective and cognitive dimensions of alexithymia. <i>Cortex</i> , 2014, 54, 190-199.	2.4	35
156	Feasibility of teaching motivational interviewing to parents of young adults with recent-onset schizophrenia and co-occurring cannabis use. <i>Journal of Substance Abuse Treatment</i> , 2014, 46, 340-345.	2.8	18
157	The effect of clozapine and risperidone on attentional bias in patients with schizophrenia and a cannabis use disorder: An fMRI study. <i>Journal of Psychopharmacology</i> , 2014, 28, 633-642.	4.0	22
158	Prevalence and correlates of depressive symptoms in a catchment-area based cohort of older community-living schizophrenia patients. <i>Schizophrenia Research</i> , 2014, 157, 285-291.	2.0	18
159	Presence of obsessive compulsive symptoms in first-episode schizophrenia or related disorders is associated with subjective well-being and quality of life. <i>Microbial Biotechnology</i> , 2013, 7, 285-290.	1.7	41
160	Moving beyond transition outcomes: Meta-analysis of remission rates in individuals at high clinical risk for psychosis. <i>Psychiatry Research</i> , 2013, 209, 266-272.	3.3	114
161	Transition to first episode psychosis in ultra high risk populations: Does baseline functioning hold the key?. <i>Schizophrenia Research</i> , 2013, 143, 132-137.	2.0	33
162	The 5-Year Course of Obsessive-Compulsive Symptoms and Obsessive-Compulsive Disorder in First-Episode Schizophrenia and Related Disorders. <i>Schizophrenia Bulletin</i> , 2013, 39, 151-160.	4.3	121

#	ARTICLE	IF	CITATIONS
163	Replicated Evidence of Absence of Association between Serum S100B and (Risk of) Psychotic Disorder. PLoS ONE, 2013, 8, e82535.	2.5	11
164	Differences in craving for cannabis between schizophrenia patients using risperidone, olanzapine or clozapine. Journal of Psychopharmacology, 2012, 26, 189-195.	4.0	30
165	Ultra high-risk state for psychosis and non-transition: A systematic review. Schizophrenia Research, 2011, 132, 8-17.	2.0	137
166	Prevalence of Psychotic Disorders in Patients with Obsessive-Compulsive Disorder. CNS Spectrums, 2009, 14, 415-418.	1.2	38
167	Cessation of cannabis use by patients with recent-onset schizophrenia and related disorders. Psychopharmacology Bulletin, 2008, 41, 142-53.	0.0	6
168	Occupancy of dopamine D2 receptors by antipsychotic drugs is related to nicotine addiction in young patients with schizophrenia. Psychopharmacology, 2006, 183, 500-505.	3.1	44
169	Reliability and validity of the Yale-Brown Obsessive-Compulsive Scale in schizophrenia patients. Psychopharmacology Bulletin, 2006, 39, 25-30.	0.0	42
170	Obsessive-Compulsive Symptoms and Positive, Negative, and Depressive Symptoms in Patients with Recent-Onset Schizophrenic Disorders. Canadian Journal of Psychiatry, 2005, 50, 519-524.	1.9	55
171	Subjective Experience and Dopamine D ₂ Receptor Occupancy in Patients Treated with Antipsychotics: Clinical Implications. Canadian Journal of Psychiatry, 2004, 49, 290-296.	1.9	59
172	School performance in secondary education shows no decline before the onset of a first episode of psychosis in schizophrenia. Journal of Mental Health, 2003, 12, 585-593.	1.9	0
173	Duration of Untreated Psychosis and Outcome of Schizophrenia: Delay in Intensive Psychosocial Treatment Versus Delay in Treatment With Antipsychotic Medication. Schizophrenia Bulletin, 2003, 29, 341-348.	4.3	88
174	Subjective Experience and D ₂ Receptor Occupancy in Patients With Recent-Onset Schizophrenia Treated With Low-Dose Olanzapine or Haloperidol: A Randomized, Double-Blind Study. American Journal of Psychiatry, 2003, 160, 303-309.	7.2	120
175	Attitudes of Patients Toward the First Psychotic Episode and the Start of Treatment. Schizophrenia Bulletin, 2002, 28, 431-442.	4.3	62
176	Obsessive-Compulsive Symptoms During Treatment With Olanzapine and Risperidone. Journal of Clinical Psychiatry, 2002, 63, 104-107.	2.2	96
177	Social Functioning and the Course of Early-Onset Schizophrenia. British Journal of Psychiatry, 2001, 179, 53-58.	2.8	92
178	Interaction of olanzapine with fluvoxamine. Psychopharmacology, 2001, 155, 219-220.	3.1	29
179	Early intervention and the course of recent onset schizophrenia. European Psychiatry, 1998, 13, 144s-144s.	0.2	0
180	Early intervention, untreated psychosis and the course of early schizophrenia. British Journal of Psychiatry, 1998, 172, 84-89.	2.8	126